Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 8/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 7/20 | 0.37 |
| ▸ | TPSB2 | P20231 | 7/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410425 | 1.00 | CFD (0.40) | CFDTACR1F11TPSB2PTPN1 | |
| SCHEMBL16410410 | 0.93 | CFD (0.41) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL17764277 | 0.93 | CFD (0.41) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL16396934 | 0.93 | CFD (0.41) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL16397032 | 0.91 | CFD (0.40) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL17764314 | 0.91 | CFD (0.41) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL16397030 | 0.91 | CFD (0.40) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL17764313 | 0.91 | CFD (0.41) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL16396609 | 0.91 | CFD (0.39) | CFDF11TPSB2PTPN1PLG | |
| SCHEMBL17772642 | 0.91 | CFD (0.39) | CFDF11TPSB2PTPN1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885TACR1 1696/4885F11 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.